Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

12.6%

51 terminated/withdrawn out of 406 trials

Success Rate

81.9%

-4.7% vs industry average

Late-Stage Pipeline

24%

98 trials in Phase 3/4

Results Transparency

23%

53 of 230 completed trials have results

Key Signals

33 recruiting53 with results47 terminated4 withdrawn

Enrollment Performance

Analytics

Phase 2

152(44.7%)

Phase 3

63(18.5%)

N/A

51(15.0%)

Phase 1

36(10.6%)

Phase 4

35(10.3%)

Early Phase 1

3(0.9%)

340Total

Phase 2(152)

Phase 3(63)

N/A(51)

Phase 1(36)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (406)

Showing 20 of 406 trials

NCT03322865Phase 2Active Not Recruiting

Obinutuzumab in Marginal Zone Lymphoma

Role: collaborator

NCT06191068Completed

Canadian CHO-KLAT/H-FIT Study - Quality of Life of, and Burden of Caring for, Persons With Hemophilia

Role: collaborator

NCT07542678Phase 2Not Yet Recruiting

Double-T - Improving Outcomes in High-risk 2nd Line Relapsed/Refractory Large B-Cell Lymphoma Patients Eligible for CAR-T-cell Therapy With a Glofitamab-based Induction and Consolidation Concept

Role: collaborator

NCT02436707Phase 2Active Not Recruiting

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Role: collaborator

NCT03341520Phase 2Completed

Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma

Role: collaborator

NCT05470595Phase 2Active Not Recruiting

A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung

Role: collaborator

NCT03449914Active Not Recruiting

The GOLD Study: G8 in OLDer Patients

Role: collaborator

NCT04363853Phase 2Active Not Recruiting

Tocilizumab Treatment in Patients With COVID-19

Role: collaborator

NCT05798156Phase 2Active Not Recruiting

Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

Role: collaborator

NCT04253561Phase 1Completed

Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients

Role: collaborator

NCT06634225Completed

Use of Inertial Units in Patient With Multiple Sclerosis (IMUSEP)

Role: collaborator

NCT05689671Phase 4Active Not Recruiting

Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma

Role: collaborator

NCT07426991Recruiting

Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis

Role: collaborator

NCT06068985Phase 2Active Not Recruiting

Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade

Role: collaborator

NCT03474094Phase 2Active Not Recruiting

Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy

Role: collaborator

NCT07365930Recruiting

NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy

Role: collaborator

NCT07387848Phase 2Not Yet Recruiting

Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas

Role: collaborator

NCT03455582Not ApplicableActive Not Recruiting

Cognition Evolution and MRI Markers in PPMS Patients on 2 Years

Role: collaborator

NCT05733611Phase 2Terminated

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

Role: collaborator

NCT04161248Early Phase 1Recruiting

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Role: collaborator